Journal article
Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model
Abstract
OBJECTIVES: Treatment of advanced NSCLC (aNSCLC) is rapidly evolving, as new targeted and immuno-oncology (I-O) treatments become available. The iTEN model was developed to predict the cost and survival benefits of changing aNSCLC treatment patterns from a Canadian healthcare system perspective. This report describes iTEN model development and validation.
MATERIALS & METHODS: A discrete event patient simulation of aNSCLC was developed. A …
Authors
Moldaver D; Hurry M; Evans WK; Cheema PK; Sangha R; Burkes R; Melosky B; Tran D; Boehm D; Venkatesh J
Journal
Lung Cancer, Vol. 139, , pp. 185–194
Publisher
Elsevier
Publication Date
January 2020
DOI
10.1016/j.lungcan.2019.10.019
ISSN
0169-5002